採用
About This Role
The Pharmaceutical Operations and Technology (PO&T) Division is looking to hire a CMC Asset Lead. This Asset Lead is a member of the Asset Development & Portfolio Management (ADPM) team which provides cross-functional leadership of development programs (assets). The PO&T Asset Lead is accountable for end-to-end asset leadership including asset strategy, development, supply and life cycle management planning for all CMC aspects of clinical programs in biologics, pharmaceuticals or other modalities. This PO&T Asset Lead role is specifically responsible for leading CMC of one or more clinical immunology programs. Programs may require alliance management of corporate partners.
This is a hybrid role based in Cambridge, MA.
What You’ll Do
-
Serve as the PO&T “asset owner” of clinical programs, with accountability for delivering a 5-year PO&T Asset Strategy, maintenance of an 18-month rolling Tactical Plan, monitoring key program risks and development of risk mitigation plans
-
Lead the cross-functional PO&T Asset Team including representatives from process/analytical development, manufacturing, quality, supply chain, device (if applicable) and regulatory CMC, in the development of and delivery on the PO&T Asset Strategy & Tactical Plan
-
Serve as PO&T’s representative on the Research and Development Program teams; acts as in influencer and liaison between Research, Development and PO&T leadership.
-
Proactively manage conflicts with the Asset Strategy (e.g., driven by other Assets and/or Line Function priorities) in consultation with the PO&T Governance Committee, Research/Development governance, or corporate partners.
-
Monitor asset-related impacts on the annual project budget and resources and cost to commercialization (e.g., expenses, COGS, excess production, OPEX) and collaborate with the PO&T Line Functions to develop tactics to improve them. Develop business cases for key asset initiatives and secure management endorsement at the PO&T Governance Committee
Who You Are
You have leadership experience in CMC drug development, supply chain or manufacturing. You will be part of ADPM and lead teams representing PO&T disciplines and maintaining critical partnerships with relevant program Research and/or Development product teams and leaders. You will be instrumental in leading and facilitating key aspects of the PO&T vision through engagement/oversight of programs transitioning into clinical development, driving best practices for resource management/forecasting, decision gates and associated knowledge management initiatives.
Qualifications
-
Advanced degree (PhD) preferred in a relevant biopharmaceutical discipline, and 10 years of relevant experience including line and matrix management. MS, MBA and/or Bachelor’s degree may be considered with extensive experience.
-
Experience in matrix leadership experience in the setting of program teams across the full product life cycle, e.g., (CMC) PO&T line functions sub-teams or other cross-functional teams operating in a matrix environment.
-
Experience with CMC in one or more areas from research to IND to NDA/BLA,. Technical expertise in one or more relevant bio/pharmaceutical development discipline.
-
Experience in healthcare/biotech/pharmaceutical industry with a demonstrated understanding of cross-functional interdependencies (i.e., Research, Development, commercial, regulatory, finance)
-
Excellent strategic, organizational, and relationship development skills
-
Demonstrated ability to lead, motivate, influence without authority a strategic direction; ability to effectively leverage and develop diverse perspectives and ideas from matrix teams and others.
-
Demonstrated communication, negotiation, problem solving and decision-making abilities
-
Demonstrated ability to identify critical program risks and develop mitigation plans – strategic or tactical - to mitigate risk, costs, and reputation of Biogen.
Job Level: Management
Additional Information
The base compensation range for this role is: $163,000.00-$225,000.00
Base salary offered is determined through an analytical approach utilizing a combination of factors including, but not limited to, relevant skills & experience, job location, and internal equity.
Regular employees are eligible to receive both short term and long-term incentives, including cash bonus and equity incentive opportunities, designed to reward recent achievements and recognize your future potential based on individual, business unit and company performance.
In addition to compensation, Biogen offers a full and highly competitive range of benefits designed to support our employees’ and their families physical, financial, emotional, and social well-being; including, but not limited to:
- Medical, Dental, Vision, & Life insurances
- Fitness & Wellness programs including a fitness reimbursement
- Short- and Long-Term Disability insurance
- A minimum of 15 days of paid vacation and an additional end-of-year shutdown time off (Dec 26-Dec 31)
- Up to 12 company paid holidays + 3 paid days off for Personal Significance
- 80 hours of sick time per calendar year
- Paid Maternity and Parental Leave benefit
- 401(k) program participation with company matched contributions
- Employee stock purchase plan
- Tuition reimbursement of up to $10,000 per calendar year
- Employee Resource Groups participation
Why Biogen?
We are a global team with a commitment to excellence, and a pioneering spirit. As a mid-sized biotechnology company, we provide the stability and resources of a well-established business while fostering an environment where individual contributions make a significant impact. Our team encompasses some of the most talented and passionate achievers who have unparalleled opportunities for learning, growth, and expanding their skills. Above all, we work together to deliver life-changing medicines, with every role playing a vital part in our mission. Caring Deeply. Achieving Excellence. Changing Lives.
At Biogen, we are committed to building on our culture of inclusion and belonging that reflects the communities where we operate and the patients we serve. We know that diverse backgrounds, cultures, and perspectives make us a stronger and more innovative company, and we are focused on building teams where every employee feels empowered and inspired. Read on to learn more about our DE&I efforts.
All qualified applicants will receive consideration for employment without regard to sex, gender identity or expression, sexual orientation, marital status, race, color, national origin, ancestry, ethnicity, religion, age, veteran status, disability, genetic information or any other basis protected by federal, state or local law. Biogen is an E-Verify Employer in the United States.
総閲覧数
0
応募クリック数
0
模擬応募者数
0
スクラップ
0
類似の求人

Technical Infrastructure Program Manager, Infrastructure Capacity Management
Amazon · Arlington, VA, USA

Lead, Program Management
L3Harris · Greenville, TX, US

1LMX Capability Development Program Director
Lockheed Martin · Bethesda, MD

Project Manager
JLL · Raleigh, NC

Program Manager, Revenue Enablement
Whatnot · New York, NY
Biogenについて

Biogen
PublicSpecializing in the treatment of neurological diseases.
5,001-10,000
従業員数
Cambridge
本社所在地
$16.2B
企業価値
レビュー
4.1
10件のレビュー
ワークライフバランス
3.8
報酬
4.2
企業文化
4.5
キャリア
3.5
経営陣
4.0
78%
友人に勧める
良い点
Supportive management and team culture
Excellent health benefits and competitive compensation
Flexible working hours and remote options
改善点
Heavy workload and long hours during deadlines
High-pressure environment leading to stress and burnout
Limited growth potential in some departments
給与レンジ
547件のデータ
M3
M4
M5
M6
Senior/L5
M3 · Product Manager M3
0件のレポート
$199,467
年収総額
基本給
$79,787
ストック
$99,734
ボーナス
$19,947
$139,627
$259,307
面接体験
47件の面接
難易度
3.5
/ 5
期間
14-28週間
内定率
36%
体験
ポジティブ 65%
普通 25%
ネガティブ 10%
面接プロセス
1
Phone Screen
2
Technical Interview
3
System Design
4
Behavioral
5
Team Fit
よくある質問
Tell me about a challenging project
System design question
Coding problem
Why this company
ニュース&話題
Goldman Sachs Adjusts Price Target on Biogen to $238 From $231, Maintains Buy Rating - marketscreener.com
marketscreener.com
News
·
1d ago
Jim Cramer Says “I Got to Reopen the File on Biogen” - Yahoo Finance
Yahoo Finance
News
·
2d ago
Biogen expands control of CD38 antibody felzartamab across global markets - Drug Discovery News
Drug Discovery News
News
·
3d ago
Biogen bullish on America with Durham Bulls team up - Fierce Pharma
Fierce Pharma
News
·
5d ago